Half-Year 2022 Financial and Clinical Trials Update

Balance sheet 30 June 2022 Equity ratio at 33% (YE 2021: 31%) and net debt to assets at 24% (YE 2021: 20%) Roche % change in CER vs CHFbn 31 Dec 2021 92.3 86.7 -6% % change in CER vs 31 Dec 2021 92.3 86.7 -6% Cash and 13.0 6.8 -43% marketable 14% 8% Current securities 38.4 27.4 -28% 22.6 23.5 liabilities +5% 42% 32% Other current 24% 27% Non- assets current 30.4 +16% liabilities 25.6 35% 27% Net debt/ Non- current 56.7 56.4 62% 65% -1% total assets: Equity 24% (Net assets) 28.3 28.9 assets 31% 33% +5% CER Constant Exchange Rates 31 Dec 30 Jun 2021 2022 31 Dec 30 Jun 2021 2022 66

View entire presentation